SecurityCELG / Celgene Corp.
InstitutionBridgewater Associates, LP
ManagerRay Dalio, Bob Prince
Shares546,369
Value $ 43,393,000
Related 151020AK0 / Celgene Corp. Bond
151020AJ3 / Celgene Corp. Bond
CELGZ / Celgene Corporation Series A Contingent Value Rights

Bridgewater Associates, LP reports 20.78% increase in ownership of CELG / Celgene Corp.

August 13, 2018 - Bridgewater Associates, LP has filed a 13F-HR form disclosing ownership of 546,369 shares of Celgene Corp. (NASDAQ:CELG) with total holdings valued at $43,393,000 USD as of June 30, 2018. Bridgewater Associates, LP had filed a previous 13F-HR on May 15, 2018 disclosing 452,364 shares of Celgene Corp. at a value of $40,355,000 USD. This represents a change in shares of 20.78 percent and a change in value of 7.53 percent during the quarter.

Other investors with positions similar to Bridgewater Associates, LP include Pnc Financial Services Group, Inc., Voya Investment Management LLC, Lgt Capital Partners Ltd., Bellevue Group AG, Gotham Asset Management, LLC, and Aviva Plc.

CELGENE CORP /DE/ has declared a standard industrial code (sic) of 2834 which is the "Pharmaceutical Preparations" industry. Bridgewater Associates, LP's top industries are "Printing, Publishing, And Allied Industries" (sic 27), "Rubber And Miscellaneous Plastics Products" (sic 30), and "Stone, Clay, Glass, And Concrete Products" (sic 32).

Bridgewater Associates, LP reports 20.78% increase in  ownership of CELG / Celgene Corp.

13F Filings

The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.

In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Effective
Date
Form Security Class CUSIP Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2018-06-30 13F-HR CELGENE COM 151020104 84.31 546,369 20.78 43,393 7.53 7,926 -4,888 -12.11
2018-03-31 13F-HR CELGENE COM 151020104 96.78 452,364 55.57 40,355 32.99 15,639 -5,629 -18.55
2017-12-31 13F-HR CELGENE COM 151020104 125.09 290,776 240.94 30,345 144.01 25,704 -7,795 -62.68
2017-09-30 13F-HR CELGENE COM 151020104 137.84 85,286 109.03 12,436 134.69 6,132 1,005 18.97
2017-06-30 13F-HR CELGENE COM 151020104 127.16 40,801 -6.01 5,299 -1.91 -332 229 4.24
2017-03-31 13F-HR CELGENE COM 151020104 43,412 5,402 5,402 0
2016-12-31 13F-HR CELGENE COM 151020104 0 -100.00 0 -100.00 -3,732 0
2016-09-30 13F-HR CELGENE COM 151020104 101.58 35,700 389.04 3,732 418.33 2,885 127 17.64
2016-06-30 13F-HR CELGENE COM 151020104 99.32 7,300 78.05 720 75.61 318 -8 -1.90
2016-03-31 13F-HR CELGENE COM 151020104 4,100 0.00 410 410 0
2015-12-31 13F-HR CELGENE COM 151020104 0 0 0 0
2015-06-30 13F-HR CELGENE COM 151020104 0 -100.00 0 -100.00 -2,801 0
2015-03-31 13F-HR CELGENE COM 151020104 127.45 24,296 -65.88 2,801 -71.82 -5,978 -1,161 -11.68
2014-03-31 13F-HR CELGENE COM 151020104 154.28 71,200 962.69 9,940 778.09 9,951 -1,143 -100.98
2013-12-31 13F-HR CELGENE COM 151020104 6,700 1,132

Related SEC Filings

CELG / Celgene Corp. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-08 sec.gov
celgenecorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 3 )*       Name of issuer:  Celgene Corp     Title of Class of Securities:  Common Stock     CUSIP Number:  151020104     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X) Rule 13d-1(b)

CELG / Celgene Corp. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-08 sec.gov
celgenecorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 3 )*       Name of issuer:  Celgene Corp     Title of Class of Securities:  Common Stock     CUSIP Number:  151020104     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X) Rule 13d-1(b)

CELG / Celgene Corp. / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-29 sec.gov
us1510201049_012418.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 6) CELGENE CORPORATION -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 151020104 -------------------------------------------------------- (CUSIP Number) December 31, 2017 --------------------------------------------------

CELG / Celgene Corp. / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-29 sec.gov
us1510201049_012418.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 6) CELGENE CORPORATION -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 151020104 -------------------------------------------------------- (CUSIP Number) December 31, 2017 --------------------------------------------------

Celgene 3G/A (Passive Acquisition of More Than 5% of Shares)

2017-02-10 sec.gov
celgenecorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 2 )*       Name of issuer:  Celgene Corp     Title of Class of Securities:  Common Stock     CUSIP Number:  151020104     Date of Event Which Requires Filing of this Statement: December 31, 2016   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X) Rule 13d-1(b)

Related News Stories

Celgene (CELG) Dips More Than Broader Markets: What You Should Know

16h zacks
Celgene (CELG - Free Report) closed the most recent trading day at $81.83, moving -0.91% from the previous trading session. This change lagged the S&P 500's 0.59% loss on the day. At the same time, the Dow lost 0.35%, and the tech-heavy Nasdaq lost 0.88%. (2-0)

The October Pause That Refreshes

2018-10-11 seekingalpha
The much-awaited correction is finally here; the question is who will step up to the plate and will actually use it as a long-term buying opportunity. (36-0)

Celgene's Ozanimod Versus Biogen's Avonex: Celgene Has the Edge

2018-10-10 biospace
Celgene Corporation presented data at the 34th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) held in Berlin, Germany with results from two Phase III trials. (2-2)

Gotham Therapeutics Launches in New York City with $54 Million Series A Financing

2018-10-10 biospace
Gotham Therapeutics launched in New York with a $54 million Series A financing. The round was co-led by founding investor Versant Ventures, Forbion and S.R. One. The investment syndicate included Celgene Corporation and Alexandria Venture Investments. (2-0)

Celgene's Otezla Meets Goal in Scalp Plaque Psoriasis Study

2018-10-09 zacks
Celgene Corporation (CELG - Free Report) announced that the phase III study, STYLE, on plaque psoriasis drug, Otezla, met its primary endpoint. (4-0)



CUSIP: 151020104